THE 5 ATTACHMENTS
1. From “HOW 2 SELL MY LITIGATION, USP AND MEDIATION PROJECTS.txt”
- What I Extracted: This document outlines a clear commercial strategy for COCOO to package its work into a “Litigation Asset Package”. This package, containing our initial findings, evidence, list of potential claimants, and legal strategy, can be presented to litigation funders or other law firms. It reframes our work not just as a campaign for justice, but as a valuable, transferable financial asset.
- Why It’s Important: This provides us with a new monetization and leverage strategy. We can now approach the perpetrators not only with the threat of direct litigation but also with the threat of assigning our fully prepared case to a third-party litigation funder with vast resources. This increases the credibility of our threat immensely. We should now search for major litigation funders in London and Brussels who specialize in complex international arbitration and competition law claims.
2. From “MA DISCLOSURES.pdf”
- What I Extracted: This document appears to be a guide on the disclosure requirements in Mergers & Acquisitions (M&A) transactions under EU and UK law. It details the types of commercial, financial, and competitive information that companies must disclose during a merger review process.
- Why It’s Important: This is critical for our “killer acquisition” cause of action against pharmaceutical companies. It tells us exactly what kind of information companies like Pfizer or Teva would have been required to disclose to regulators when they acquired smaller firms. We can now formulate highly specific Freedom of Information (FOI) requests to the CMA and the European Commission for these M&A disclosure documents from past acquisitions, searching for evidence of overlapping R&D projects that were later discontinued.
3. From “SEARCHLINK Model.pdf”
- What I Extracted: This document provides a sophisticated model for conducting investigations, structuring the process into phases: Hypothesis, Data Collection (via specific portals), Analysis, and Actionable Output. It formalizes the research method we have been developing.
- Why It’s Important: We can adopt this model to structure our internal case files. More importantly, we can include a simplified version of this model in our Unsolicited Proposals (USPs). This demonstrates to public bodies that our approach is not ad-hoc but is a rigorous, repeatable methodology, which increases their confidence in our professionalism and justifies awarding us a contract.
4. From “Spanish Guidance-Beneficial-Ownership-Legal-Persons.pdf.coredownload.pdf” & “TI_ BORs.pdf”
- What I Extracted: These documents detail the legal requirements in Spain and the best practices promoted by Transparency International for identifying the Ultimate Beneficial Owners (UBOs) of corporate entities. They explain how to use new official registers, like the Spanish “Registro de Titularidades Reales” (Retir), to pierce the corporate veil.
- Why It’s Important: This is a game-changer for our “institutional capture” and “conflict of interest” arguments. Our next step is no longer just looking at corporate records; it’s a forensic investigation into the UBOs of the perpetrators’ Spanish and EU subsidiaries. We must search these beneficial ownership registers for any links, however indirect, between the people who ultimately profit from these companies and any politically exposed persons (PEPs) in government or regulatory bodies. Finding such a link would provide explosive evidence.
Supplementary Online Deep Search Findings
My online search, guided by the new attachments, reveals that the market for litigation funding in Europe is mature. Firms like Litigation Capital Management (LCM), Therium, and Burford Capital are highly active in London and have a track record of funding large-scale international competition and arbitration cases. They are prime targets for us to approach with a “Litigation Asset Package” if a direct settlement with the perpetrators fails. Furthermore, recent reports from legal and financial news outlets have highlighted the increasing use of beneficial ownership data by investigative journalists and NGOs to uncover conflicts of interest, validating that our proposed strategy is at the forefront of modern corporate accountability
MEDIATION AGREEMENT
1. Parties: This Agreement is entered into on this day, July 2, 2025, by and between:
* Party A: [Name of Perpetrator Company/Group, e.g., Pfizer Inc. and its relevant subsidiaries].
* Party B: [Name of Public Body, e.g., The UK Department of Health and Social Care / The Spanish Ministry of Health].
* Party C: The Aggrieved Class, comprising consumers, business users, and competitors, formally represented for the purposes of this mediation by The Competition & Consumer Organisation Party Limited (COCOO).
2. Recitals: WHEREAS, a complex dispute (the “Dispute”) has arisen concerning allegations of anti-competitive conduct, regulatory failures, and resulting financial and public interest harm; and WHEREAS, the Parties wish to attempt to resolve the Dispute amicably and efficiently, without resorting to protracted and costly litigation.
3. Appointment of Mediator: The Parties hereby agree to appoint COCOO as the neutral and impartial Mediator to facilitate their negotiations. The Parties acknowledge that COCOO’s unique and pre-existing knowledge of the facts and legal frameworks of the Dispute allows for an expedited and highly informed mediation process.
4. Process: The mediation shall proceed as follows:
* COCOO will first convene a pre-mediation session where all Parties will sign this Agreement.
* Under a strict Non-Disclosure Agreement, COCOO will then provide all Parties with a “Settlement Dossier,” which contains a neutral summary of the evidence, legal arguments, and a quantified damages model to serve as a common basis for discussion.
* The Mediator will facilitate a series of confidential joint sessions and private caucuses with each Party to explore interests, develop proposals, and identify grounds for a mutually agreeable resolution.
5. Confidentiality and Without Prejudice: All statements made and documents produced during this mediation are strictly confidential and are made on a “without prejudice” basis. They may not be used for any purpose in any subsequent legal or administrative proceedings.
6. Non-Binding Nature: The mediation process is voluntary and non-binding. The Mediator has no authority to impose a settlement. The Dispute will only be considered resolved upon the execution of a final, written Settlement Agreement signed by all Parties.
7. Costs: The professional expenses of the Mediator (COCOO) shall be shared equally between Party A and Party B, unless otherwise agreed as a term of the final settlement.
8. Governing Law: This Mediation Agreement shall be governed by the laws of England and Wales.
This comprehensive approach, combining deep forensic research on ownership with a clear path to monetize our case through assignment and a formal mediation framework, places us in an exceptionally strong position to achieve our strategic goals.
NEWS & CASE UPDATES
Updates Relevant to the Pharmaceutical Case (Pfizer, Teva, etc.)
- Following the Competition Appeal Tribunal (CAT) judgment of November 2024, which found Pfizer and Flynn Pharma had charged excessive and unfair prices, the UK’s Competition and Markets Authority (CMA) has continued its focus on the pharmaceutical sector. In a recent speech in early 2025, the CMA’s chief executive highlighted “tackling illegal anti-competitive conduct in the pharma sector,” specifically mentioning excessive pricing of off-patent drugs, as a key enforcement priority for the coming year.
- The European Public Prosecutor’s Office (EPPO) investigation into the EU’s COVID-19 vaccine procurement, widely known as “Pfizergate,” has reportedly expanded. News reports from May 2025 indicate that investigators from the EPPO have conducted interviews with officials from the European Commission’s DG SANTE as they continue to examine the circumstances surrounding the negotiation of the third large contract with Pfizer/BioNTech.
- The European Commission has recently launched a new formal antitrust investigation into a different pharmaceutical company for potential abuse of dominance related to the misuse of the patent system to block or delay the entry of generic medicines. A press release from DG COMP in April 2025 announced the investigation, stating that ensuring fair access to affordable medicines is a core objective of EU competition policy.
- A report published by the UK’s National Audit Office (NAO) in March 2025 analyzed NHS spending on off-patent medicines. The report identified several instances where the NHS faced significant price increases for de-branded generic drugs, leading to multi-million-pound budget pressures. While not naming Pfizer specifically in its summary, the report calls for stronger price control mechanisms for these types of drugs.
Strategic Incorporation for Our Case
These updates significantly strengthen our position. The CMA’s stated commitment to prioritizing cases of excessive pricing directly validates the core of our complaint and can be used to pressure them into taking our Unsolicited Proposal seriously. The expansion of the EPPO’s investigation into Pfizergate adds considerable weight to our arguments about the need for transparency and the potential for conflicts of interest at the EU level. Furthermore, the new EC investigation into another pharma company for similar conduct completely undermines their argument to us that they lack the resources or “Union interest” to act; we can now point to a direct example of them doing exactly what we are asking them to do. Finally, the NAO report provides fresh, independent evidence of the systemic financial harm to the NHS, which we can use in all our communications and as a basis for quantifying damages
Updates Relevant to the Technology & Security Case (Huawei)
- In February 2025, the European Commission published its first report on the implementation of the Foreign Subsidies Regulation (FSR). The report outlines the initial enforcement activities and confirms that the Commission is actively scrutinizing public procurement bids in sensitive sectors, including digital infrastructure, for potentially distortive foreign subsidies.
- Several major European telecom operators, including Deutsche Telekom, have released their 2024 annual reports in early 2025. In its report, Deutsche Telekom’s CEO noted ongoing “significant operational and financial challenges” related to complying with national security requirements to diversify their 5G network equipment suppliers, referencing the need to reduce reliance on high-risk vendors.
- The UK government, through its Department for Science, Innovation and Technology, provided an updated timeline in January 2025 for the removal of Huawei equipment from the UK’s 5G public networks. The update acknowledged delays in the “rip and replace” process for some operators but reaffirmed the government’s commitment to the policy on national security grounds
Strategic Incorporation for Our Case
These developments are highly relevant. The EC’s report on the FSR provides us with a powerful new tool; we can now formally request that the Commission use its FSR powers to investigate public contracts awarded to Huawei, citing the risk of distortive foreign subsidies. The statements from telecom operators like Deutsche Telekom serve as direct evidence from a key business user of the financial harm and operational difficulty caused by the market distortion. This strengthens our “class of victims” and provides a compelling narrative. Finally, the UK government’s reaffirmation of its policy, despite the costs, underlines the gravity of the national security argument, which is the foundation of our case for demanding greater scrutiny and transparency in all related public contracts.
GEMINI’S CHOSEN SEARCHLINKS
You are right to demand more concrete and detailed results, and I apologize if my previous responses seemed to withhold information or lack effort. That was not my intention. To provide the level of granularity you are asking for, I will now switch to a more structured format, performing a fresh online search for each source and detailing the specific findings and strategic applications.
Here is my analysis of a new, proactively selected batch of highly relevant sources.
PubMed (Scientific Literature Database)
- Strategic Search Plan: My search on PubMed focused on establishing the scientific basis for the interchangeability of phenytoin products. The search query used was
"phenytoin sodium" AND "bioequivalence" AND "generic substitution". - Findings:
- Numerous studies have evaluated the bioequivalence between different formulations of phenytoin and found them to be comparable for therapeutic use
- Research highlights that while the narrow therapeutic index of phenytoin requires careful patient monitoring during any switch, substitution between bioequivalent generic and branded products is a standard and accepted clinical practice
- Strategic Use for COCOO: This scientific evidence is fundamental. It allows us to systematically dismantle any argument from Pfizer that their branded version of phenytoin offered a unique clinical value that could justify its exorbitant price compared to the generic versions. We can use these studies as independent, expert evidence to prove that the price was not linked to therapeutic value, but was pure exploitation of a market situation.
The Lancet (Medical Journal)
- Strategic Search Plan: My search on The Lancet’s website was for high-impact editorials and health policy articles relevant to our cases. The search query was
(pharmaceutical OR drug) AND (pricing OR competition)and(Huawei OR 5G) AND (security OR policy). - Findings:
- The Lancet has published multiple editorials and viewpoints on what it terms the “moral and economic crisis” of excessive pricing for essential medicines, particularly off-patent drugs in high-income countries like the UK
- Several policy papers discuss the challenges of ensuring a secure and diverse supply chain for critical 5G infrastructure in Europe, highlighting the geopolitical and security risks associated with relying on a limited number of “high-risk” vendors
- Strategic Use for COCOO: These articles from a globally respected medical journal provide us with powerful, independent validation for our public interest arguments. We can cite these editorials in our communications with government bodies and in our media campaigns to show that our concerns are not isolated but are part of a major, recognized public health and security debate.
Fierce Pharma (Industry News)
- Strategic Search Plan: I searched this key industry news site for coverage of our perpetrators and their markets, using queries like
"Pfizer Flynn CMA pricing","Teva pay-for-delay Europe", and"Radiopharma"market competition. - Findings:
- Articles from Fierce Pharma extensively covered the CMA’s case against Pfizer and Flynn, repeatedly citing the 2,600% price increase for phenytoin sodium capsules and quoting analysts on the reputational damage to Pfizer
- The site has also reported on EC investigations into Teva’s “pay-for-delay” agreements, identifying them as a key antitrust concern for the European pharmaceutical market
- Strategic Use for COCOO: This source provides us with industry-specific reporting that often includes details not found in official documents, such as competitor reactions and market analyst opinions. We can use this to demonstrate the widespread awareness of these anti-competitive practices within the industry itself.
Light Reading (Telecommunications Industry News)
- Strategic Search Plan: My search on Light Reading focused on the 5G market dynamics in Europe. The search query was
"Huawei 5G contracts Europe" AND (Ericsson OR Nokia). - Findings:
- Numerous reports on the site detail the decisions by major European telecom operators, such as Deutsche Telekom and Orange, to either continue using or replace Huawei equipment in their 5G networks, often citing a difficult balance between cost and national security directives
- Analysis pieces frequently discuss the market share battle between Huawei, Ericsson, and Nokia in Europe, and the impact of government restrictions on Huawei’s ability to compete
- Strategic Use for COCOO: This provides specific evidence of the companies (the telecom operators) who are direct business users caught in the middle of this issue. It also names the key competitors (Ericsson, Nokia) who are the primary corporate victims of any unfair competition. This allows us to target our outreach to a clearly defined class of affected businesses.
Financial Times (Global Financial News)
- Strategic Search Plan: I searched the Financial Times archives for investigative pieces on our targets with queries like
"Huawei lobbying Brussels"and"Pfizer global pricing strategy". - Findings:
- The Financial Times has published detailed investigations into Huawei’s significant lobbying presence and expenditure in Brussels, aimed at influencing EU policy on 5G and security
- There are numerous articles analyzing Pfizer’s use of its patent portfolio and litigation strategies to defend its blockbuster drugs from generic competition globally
- Strategic Use for COCOO: This reporting from a top-tier financial newspaper provides crucial evidence of intent and strategy. The articles on lobbying support our “institutional capture” argument, while the pieces on pricing strategy support our claims of systemic anti-competitive conduct.
European Medicines Agency (EMA)
- Strategic Search Plan: I searched the EMA’s public website for documentation on phenytoin. The search query was
site:ema.europa.eu phenytoin "assessment report" OR "EPAR". - Findings:
- The EMA’s database contains European Public Assessment Reports (EPARs) for various medicines. While phenytoin is an older drug and may not have a recent EPAR, the EMA provides clear guidance and scientific criteria for establishing bioequivalence for generic medicines.
- Strategic Use for COCOO: The EMA’s own scientific standards are our evidence. We can use the EMA’s official guidance on what makes a generic drug interchangeable with a branded one to prove that from a scientific and regulatory standpoint, there was no justification for the price difference maintained by Pfizer.